Bioventus Inc. 8-KCurrent Reports (8-K / ad hoc)

Market for Equity / Stockholders

Item 5.07. Submission of Matters to a Vote of Security Holders. Bioventus, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”) on June 3, 2026. A total of 75,279,174 shares (the “Shares”) of both Class A common stock and Class B common stock (collectively, the “Common Stock”) were present in person or represented by proxy at the 2026 Annual Meeting, representing approximately 90.23% of the outstanding Shares of Common Stock entitled to vote as a single class as of the April 6, 2026 record date. The following proposals were voted upon at the 2026 Annual Meeting and the final voting results with respect to each such proposal are set forth below. At the 2026 Annual Meeting, the stockholders elected the following directors to serve on the Company’s Board of Directors until the 2027 annual meeting of stockholders and until each such director’s respective successor is elected and qualified, or until each such director’s death, resignation or removal, based on the following votes: Nominee For Withheld Broker Non-Votes William A. Hawkins 67,405,961 1,128,994 6,744,219 John A. Bartholdson 68,365,980 168,975 6,744,219 Patrick J. Beyer 68,062,114 472,841 6,744,219 Robert E. Claypoole 68,360,467 174,488 6,744,219 Philip G. Cowdy 67,748,512 786,443 6,744,219 Ajay Dhankhar 68,459,149 75,806 6,744,219 Mary Kay Ladone 67,160,936 1,374,019 6,744,219 Michelle McMurry-Heath 68,073,685 461,270 6,744,219 Guido J. Neels 68,049,659 485,296 6,744,219 Guy P. Nohra 67,767,651 767,304 6,744,219 Susan M. Stalnecker 68,060,987 473,968 6,744,219 Martin P. Sutter 61,710,650 6,824,305 6,744,219 The stockholders also ratified the appointment of Grant Thornton LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The vote for such ratification was 75,228,481 Shares for, 5,021 Shares against, 45,672 Shares abstaining, and no broker non-votes. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOVENTUS INC. Date: June 4, 2026 By: /s/ Anthony D’Adamio Anthony D’Adamio Senior Vice President and General Counsel